Evidence map›Paper›PMID 30620772›Full record

SynthesisPloS one2019

Cardiovascular risk prediction models for women in the general population: A systematic review.

Sara J Baart, Veerle Dam, Luuk J J Scheres, Johanna A A G Damen, René Spijker, Ewoud Schuit, Thomas P A Debray, Bart C J M Fauser, Eric Boersma, Karel G M Moons and 2 more

Abstract readSystematic ReviewValidation Study
In one paragraph

Synthesis in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Review
  8. Article
  9. The value of pregnancy-related factors in the prediction of cardiovascular disease: a systematic review.International journal of cardiology. Cardiovascular risk and prevention · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Major Limitations of Cardiovascular Risk Scores.Cardiovascular therapeutics · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sara J BaartDepartment of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands.
Veerle DamNetherlands Heart Institute, Utrecht, the Netherlands.
Luuk J J ScheresNetherlands Heart Institute, Utrecht, the Netherlands.ORCID 0000-0001-5282-5520
Johanna A A G DamenJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0001-7401-4593
René SpijkerJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Ewoud SchuitJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Thomas P A DebrayJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0002-1790-2719
Bart C J M FauserDepartment of Reproductive Medicine & Gynaecology, University Medical Center, Utrecht University, the Netherlands.
Eric BoersmaDepartment of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands.
Karel G M MoonsJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Yvonne T van der SchouwJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
CREW consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo provide a comprehensive overview of cardiovascular disease (CVD) risk prediction models for women and models that include female-specific predictors.

methodsWe performed a systematic review of CVD risk prediction models for women in the general population by updating a previous review. We searched Medline and Embase up to July 2017 and included studies in which; (a) a new model was developed, (b) an existing model was validated, or (c) a predictor was added to an existing model.

resultsA total of 285 prediction models for women have been developed, of these 160 (56%) were female-specific models, in which a separate model was developed solely in women and 125 (44%) were sex-predictor models. Out of the 160 female-specific models, 2 (1.3%) included one or more female-specific predictors (mostly reproductive risk factors). A total of 591 validations of sex-predictor or female-specific models were identified in 206 papers. Of these, 333 (56%) validations concerned nine models (five versions of Framingham, SCORE, Pooled Cohort Equations and QRISK). The median and pooled C statistics were comparable for sex-predictor and female-specific models. In 260 articles the added value of new predictors to an existing model was described, however in only 3 of these female-specific predictors (reproductive risk factors) were added.

conclusionsThere is an abundance of models for women in the general population. Female-specific and sex-predictor models have similar predictors and performance. Female-specific predictors are rarely included. Further research is needed to assess the added value of female-specific predictors to CVD models for women and provide physicians with a well-performing prediction model for women.

Indexed as

Cardiovascular DiseasesCohort StudiesFemaleHumansModels, CardiovascularModels, StatisticalRisk AssessmentRisk FactorsSex Factors

Identifiers

PMID30620772
PMCPMC6324808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.